Ausgabe 6/2018
Inhalt (19 Artikel)
Wnt/β-catenin signaling mediates the suppressive effects of diallyl trisulfide on colorectal cancer stem cells
Qi Zhang, Xiao-Ting Li, Yue Chen, Jia-Qi Chen, Jian-Yun Zhu, Yu Meng, Xiao-Qian Wang, Yuan Li, Shan-Shan Geng, Chun-Feng Xie, Jie-Shu Wu, Cai-Yun Zhong, Hong-Yu Han
Correction to: Wnt/β-catenin signaling mediates the suppressive effects of diallyl trisulfide on colorectal cancer stem cells
Qi Zhang, Xiao-Ting Li, Yue Chen, Jia-Qi Chen, Jian-Yun Zhu, Yu Meng, Xiao-Qian Wang, Yuan Li, Shan-Shan Geng, Chun-Feng Xie, Jie-Shu Wu, Cai-Yun Zhong, Hong-Yu Han
Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
Sakura Iizumi, Atsuo Takashima, Kentaro Sakamaki, Satoshi Morita, Narikazu Boku
Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer
James D. Byrne, Mohammad R. N. Jajja, Adrian T. O’Neill, Allison N. Schorzman, Amanda W. Keeler, J. Christopher Luft, William C. Zamboni, Joseph M. DeSimone, Jen Jen Yeh
Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner
Fei Wu, Yun Lin, Peng Cui, Hongyun Li, Lechao Zhang, Zeqiang Sun, Shengliang Huang, Shun Li, Shiming Huang, Qingli Zhao, Qingyong Liu
Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer
Yan-qin Lan, Ling-jun Kong, Xiao-yan Lin, Qian Xu, Xin-yan Gao, Ri-ping Wu, Xin-li Wang, Dong-ta Zhong
A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer
Masato Ozaka, Hiroshi Ishii, Tosiya Sato, Makoto Ueno, Masafumi Ikeda, Kazuhiro Uesugi, Naohiro Sata, Kouichirou Miyashita, Nobumasa Mizuno, Kunihiro Tsuji, Takuji Okusaka, Junji Furuse
Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice
Aiping Tian, Haizhen Lu, Jingxuan Zhang, Shilan Fu, Zaoli Jiang, Wing Lam, Fulan Guan, Linlin Chen, Li Feng, Yungchi Cheng
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study
Chu Matsuda, Michitaka Honda, Chihiro Tanaka, Ken Kondo, Takao Takahashi, Chihiro Kosugi, Yukihiko Tokunaga, Hiroyoshi Takemoto, Ho Min Kim, Junichi Sakamoto, Koji Oba, Hideyuki Mishima
Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer
Toshirou Fukushima, Yuuki Wakatsuki, Takashi Kobayashi, Kei Sonehara, Kazunari Tateishi, Manabu Yamamoto, Takeshi Masubuchi, Fumiaki Yoshiike, Kazuya Hirai, Tsutomu Hachiya, Tomonobu Koizumi
Antiproteinuric effects of renin–angiotensin inhibitors in lung cancer patients receiving bevacizumab
Satoru Nihei, Junya Sato, Toshiyuki Harada, Shoichi Kuyama, Toshiro Suzuki, Nobutsugu Waga, Yoshitaka Saito, Shigeki Kisara, Atsuko Yokota, Kouji Okada, Masami Tsuchiya, Kazufumi Terui, Yumiko Tadokoro, Takeshi Chiba, Kenzo Kudo, Satoshi Oizumi, Akira Inoue, Naoto Morikawa
Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
Steven Lacy, Jace Nielsen, Bei Yang, Dale Miles, Linh Nguyen, Matt Hutmacher
A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types
Steven Lacy, Bei Yang, Jace Nielsen, Dale Miles, Linh Nguyen, Matt Hutmacher
A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification
Bo Xu, Yuyou Deng, Ran Bi, Haoran Guo, Chang Shu, Neelam Kumari Shah, Junliang Chang, Guanchen Liu, Yujun Du, Wei Wei, Chunxi Wang
Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein
George E. Duran, Volker Derdau, Dietmar Weitz, Nicolas Philippe, Jörg Blankenstein, Jens Atzrodt, Dorothée Sémiond, Diego A. Gianolio, Sandrine Macé, Branimir I. Sikic
Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases
Kohei Fujita, Naohiro Uchida, Osamu Kanai, Misato Okamura, Koichi Nakatani, Tadashi Mio
IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1)
Jing Du, Yuanqiao He, Peng Li, Weiquan Wu, Youwei Chen, Hongjun Ruan
Acceleration of carboxylesterase-mediated activation of irinotecan to SN-38 by serum from patients with end-stage kidney disease
Hiroyoshi Koide, Masayuki Tsujimoto, Yurie Katsube, Megumi Ochiai, Ayako Hojo, Taku Furukubo, Satoshi Izumi, Tomoyuki Yamakawa, Daisuke Shima, Tetsuya Minegaki, Kohshi Nishiguchi
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies
Boaz Mendzelevski, Georg Ferber, Filip Janku, Bob T. Li, Ryan J. Sullivan, Dean Welsch, Wei Chi, Jeanne Jackson, Onglee Weng, Philip T. Sager